Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that it has entered into its first concierge medicine contract with LEAA Health. The contract provides LEEA Health’s membership-based patients access to groundbreaking esophageal precancer testing using Lucid’s EsoGuard Esophageal DNA Test. This expands LEAA Health’s enhanced personalized care services, which it offers to its patients on a cash-pay basis.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD: